{
    "clinical_study": {
        "@rank": "67194", 
        "arm_group": {
            "arm_group_label": "Zipsor\u00ae (Liquid filled capsules)", 
            "arm_group_type": "Experimental", 
            "description": "25mg/every 6hrs/up to 4 days treatment"
        }, 
        "brief_summary": {
            "textblock": "As part of the PREA(Pediatric Research Equity Act) commitment, the objective of the study is\n      to confirm safety and tolerability of 25 mg of Zipsor\u00ae in clinical pediatric subjects."
        }, 
        "brief_title": "Safety and Tolerability of Zipsor\u00ae in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "Open-label study, subjects will be dosed with Zipsor\u00ae for the treatment of mild to moderate\n      acute pain for up to 4 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects between 12-17 years of age.\n\n          -  Subjects must be post-op, having mild or moderate acute pain.\n\n        Other inclusions apply.\n\n        Exclusion Criteria:\n\n          -  Subject has a known history of allergic reaction, hypersensitivity to diclofenac,\n             aspirin, acetaminophen, or reaction to the non-active ingredients of the study\n             medication.\n\n          -  Subject has been taking analgesic for 48-72 hours prior to Screening.\n\n          -  Subject has a history of any GI event greater than 6 months before Screening.\n\n          -  Subject is currently receiving any medication that is contraindicated for use\n             concomitantly with diclofenac or acetaminophen.\n\n          -  Subject has previously participated in another clinical study of Zipsor or taking\n             Zipsor for any other indication.\n\n          -  Subject is requiring treatment for pre-existing hypertension.\n\n        Other exclusions apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982539", 
            "org_study_id": "81-0072"
        }, 
        "intervention": {
            "arm_group_label": "Zipsor\u00ae (Liquid filled capsules)", 
            "description": "Administration of Zipsor\u00ae (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.", 
            "intervention_name": "Zipsor\u00ae", 
            "intervention_type": "Drug", 
            "other_name": "Diclofenac"
        }, 
        "intervention_browse": {
            "mesh_term": "Diclofenac"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pain", 
            "NSAID", 
            "moderate pain", 
            "mild pain", 
            "acute pain", 
            "mild acute pain", 
            "moderate acute pain", 
            "mild or moderate acute pain"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35660"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-5640"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study of the Safety and Efficacy of Zipsor\u00ae (Diclofenac Potassium) Liquid Filled Capsules in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute Pain", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety Endpoints:\nTreatment emergent AEs (TEAEs)\nSerious adverse events (SAEs)\nWithdrawals due to AEs\nDeaths\nObserved values and changes in vital sign measurements\nObserved values and changes in clinical laboratory results\nPhysical examination findings", 
            "measure": "To confirm the safety and tolerability of Zipsor\u00ae in pediatric subjects, ages 12 to 17 years", 
            "safety_issue": "No", 
            "time_frame": "up to 4-days of Zipsor treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982539"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To determine efficacy by assessing percent changes of the Numeric Pain Rating Scale (NPRS) pain score from baseline to (1) the first hour and (2) the second hour after the first dose of Zipsor\u00ae administration.", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "From Baseline to 1st and 2nd hour"
        }, 
        "source": "Depomed", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Depomed", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}